Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of TYK-00540 plus enzalutamide in metastatic castration-resistant prostate cancer after failure of one prior novel endocrine therapy
CTR20252940Phase 2Active
- Sponsor
- TYK Medicines
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of TYK-00540 and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by TYK Medicines. Primary endpoints: Safety and dose-limiting toxicity in dose escalation and Radiographic progression-free survival in dose expansion. Started Jul 2025; status: active.
02
Drugs
TYK-00540enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20252940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252940.